Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Statement of Comprehensive Income [Abstract]
Revenues	$ 92,207	$ 80,316	$ 181,414	$ 159,798
Cost of revenues	53,784	49,452	106,474	98,808
Gross profit	38,423	30,864	74,940	60,990
Operating expenses:
Selling and marketing	16,116	14,518	31,370	29,066
Research and development	7,961	6,622	15,115	12,496
Distribution	7,015	6,255	14,068	12,626
General and administrative	8,511	8,585	16,542	17,497
Total operating expenses	39,603	35,980	77,095	71,685
Loss from operations	(1,180)	(5,116)	(2,155)	(10,695)
Other income (expense):
Interest expense, net	(288)	(242)	(529)	(483)
Other (expense) income, net	(409)	37	(641)	301
Total other expense	(697)	(205)	(1,170)	(182)
Net loss before income taxes	(1,877)	(5,321)	(3,325)	(10,877)
Provision for income taxes	348	273	683	580
Net loss	(2,225)	(5,594)	(4,008)	(11,457)
Less: Net loss attributable to noncontrolling interests	(493)	(267)	(1,000)	(472)
Net loss attributable to stockholders of NxStage Medical, Inc.	$ (1,732)	$ (5,327)	$ (3,008)	$ (10,985)
Net loss per share, basic and diluted (in dollars per share)	$ (0.03)	$ (0.08)	$ (0.05)	$ (0.17)
Weighted-average shares outstanding, basic and diluted (in shares)	64,428	63,288	64,302	63,059
Other comprehensive loss, net of tax	$ (1,280)	$ (154)	$ (219)	$ (930)
Total comprehensive loss	(3,505)	(5,748)	(4,227)	(12,387)
Less: Comprehensive loss attributable to noncontrolling interests	(493)	(267)	(1,000)	(472)
Total comprehensive loss attributable to stockholders of NxStage Medical, Inc.	$ (3,012)	$ (5,481)	$ (3,227)	$ (11,915)